☆ 4.7 Review

Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A systematic review and meta-analysis

FRONTIERS IN ENDOCRINOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Short-term ADT and Dose-escalated IMRT in Patients With Intermediate-risk Prostate Cancer Benefit or Caution?

Carl M. Post et al.

Summary: This retrospective analysis evaluated the outcomes of intermediate-risk prostate cancer patients treated with dose-escalated intensity modulated radiation therapy (IMRT) with or without short-term concurrent androgen deprivation therapy (ADT). The results showed that short-term ADT was associated with significantly worse overall survival.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer

Hideyasu Tsumura et al.

Summary: This study compared the clinical outcomes of seed brachytherapy alone and seed brachytherapy plus external-beam radiotherapy for intermediate-risk prostate cancer. The results showed that seed brachytherapy alone had a higher biochemical recurrence-free rate and fewer late toxicities.

SCIENTIFIC REPORTS (2022)

添加到收藏夹

Review Medicine, General & Internal

Anti-cancer therapy made easier: a 25-year update

Amy Davies et al.

Summary: Supportive care is crucial in cancer treatment to improve tolerability and quality of life for patients. With advancements in anti-cancer therapies, the support measures are continuously evolving to meet the needs of patients.

INTERNAL MEDICINE JOURNAL (2021)

添加到收藏夹

Article Oncology

Cancer Statistics, 2021

Rebecca L. Siegel et al.

Summary: Every year, the American Cancer Society projects the numbers of new cancer cases and deaths in the United States, with the latest data showing a significant decline in lung cancer mortality, while prostate cancer mortality has plateaued and breast and colorectal cancer mortality have slowed. Improvements in treatment have accelerated progress against lung cancer, leading to a record drop in overall cancer mortality.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Review Endocrinology & Metabolism

Hormonal Therapy for Prostate Cancer

Kunal Desai et al.

Summary: Huggins and Hodges demonstrated the therapeutic effect of gonadal testosterone deprivation in the 1940s, leading to the concept of prostate cancer being highly androgen-dependent. Since then, hormonal therapy has evolved from gonadal testosterone deprivation to inhibiting extragonadal androgens, to directly binding and inhibiting the androgen receptor. Today's standard of care for advanced prostate cancer includes gonadotropin-releasing hormone agonists and androgen receptor antagonists.

ENDOCRINE REVIEWS (2021)

添加到收藏夹

Article Oncology

Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial

Abdenour Nabid et al.

Summary: The study demonstrates that in patients with intermediate-risk prostate cancer, the combination of ADT with radiotherapy can significantly improve biochemical failure rates and decrease progression and death rates compared with radiotherapy alone. Higher dose radiotherapy (76 Gy) may increase gastrointestinal toxicity, with no significant difference in overall survival.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Dose Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Suppression for Intermediate Risk Prostate Cancer: Outcomes From the NRG Oncology/RTOG 0815 Randomized Trial

D.J. Krauss et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

添加到收藏夹

Article Oncology

Randomized Phase III Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate: Analysis of Quality of Life and Toxicity, PCG GU 003

C.S. Thorpe et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Review Urology & Nephrology

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

Nicolas Mottet et al.

Summary: The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on screening, diagnosis, and treatment of localized prostate cancer summarize the most recent recommendations for clinical practice, including risk-adapted strategies, medical imaging utilization, biopsy techniques, patient classification, and treatment options. Recommendations include consideration of moderate hypofractionation for intermediate-risk patients and a combination of local treatment with long-term hormonal therapy for cN1 PCa patients.

EUROPEAN UROLOGY (2021)

添加到收藏夹

Article Oncology

Prostate Cancer, Version 1.2021 Featured Updates to the NCCN Guidelines

Edward Schaeffer et al.

Summary: The NCCN Guidelines for Prostate Cancer provide recommendations for staging and risk assessment post-diagnosis, with management options for localized, regional, and metastatic disease. The guidelines also cover disease monitoring and treatment of recurrent disease. The NCCN Prostate Cancer Panel meets annually to update recommendations based on new clinical data, aiming to provide the most effective care for patients.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

添加到收藏夹

Article Oncology

Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial

Abdenour Nabid et al.

Summary: This study aimed to determine the impact of different treatment regiments based on prognostic factors in patients with intermediate-risk prostate cancer. Results showed that in unfavorable intermediate risk patients, the ADT + DERT76 group had a significant survival advantage.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

添加到收藏夹

Review Medicine, General & Internal

Prostate cancer

Shahneen Sandhu et al.

Summary: Management of prostate cancer is rapidly evolving with advances in understanding the genomic landscape, improved imaging methods, and personalised therapeutics targeting DNA repair pathways. The therapeutic framework for metastatic disease has shifted, with oligometastatic disease being evaluated for metastatic-directed therapies, and novel androgen pathway inhibitors showing significant survival benefits as first-line therapy for metastatic disease. Emerging research into molecular characterisation and novel therapeutics, such as targeted radioisotopes and immunotherapy, hold promise for improving patient outcomes.

LANCET (2021)

添加到收藏夹

Article Oncology

Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer Statement from the DEGRO working group on prostate cancer

Marcus Beck et al.

STRAHLENTHERAPIE UND ONKOLOGIE (2020)

添加到收藏夹

Editorial Material Oncology

Rates of advanced prostate cancer continue to increase

Mike Fillon

CA-A CANCER JOURNAL FOR CLINICIANS (2020)

添加到收藏夹

Letter Oncology

Role of Androgen-Deprivation Therapy Remains Uncertain for Intermediate-Risk Patients When Using Dose-Escalated Radiotherapy

Marisa A. Kollmeier et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Letter Medicine, General & Internal

Effect of Androgen Deprivation on Long-term Outcomes of Intermediate-Risk Prostate Cancer Stratified as Favorable or Unfavorable A Secondary Analysis of the RTOG 9408 Randomized Clinical Trial

Zachary S. Zumsteg et al.

JAMA NETWORK OPEN (2020)

添加到收藏夹

Article Medicine, General & Internal

Prostate Cancer Screening

William J. Catalona

MEDICAL CLINICS OF NORTH AMERICA (2018)

添加到收藏夹

Review Endocrinology & Metabolism

Bone health during endocrine therapy for cancer

Tilman D. Rachner et al.

LANCET DIABETES & ENDOCRINOLOGY (2018)

添加到收藏夹

Article Oncology

High intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy

Tom Pickles et al.

BRACHYTHERAPY (2017)

添加到收藏夹

Article Oncology

PMH 9907: Long-Term Outcomes of a Randomized Phase 3 Study of Short-Term Bicalutamide Hormone Therapy and Dose-Escalated External-Beam Radiation Therapy for Localized Prostate Cancer

Andrew J. McPartlin et al.

CANCER (2016)

添加到收藏夹

Article Oncology

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer

Danielle Crawley et al.

INTERNATIONAL JOURNAL OF CANCER (2016)

添加到收藏夹

Meeting Abstract Oncology

Does short-term androgen depletion add to high dose radiotherapy (80 Gy) in localized intermediate risk prostate cancer? Final analysis of GETUG 14 randomized trial (EU-20503/NCT00104741)

Bernard M. Dubray et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Localized prostate cancer treated with external beam radiation therapy: Long-term outcomes at a European comprehensive cancer centre

Anna Boladeras et al.

REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY (2016)

添加到收藏夹

Review Urology & Nephrology

Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis

Cecilia Bosco et al.

EUROPEAN UROLOGY (2015)

添加到收藏夹

Article Oncology

Additional androgen deprivation makes the difference Biochemical recurrence-free survival in prostate cancer patients after HDR brachytherapy and external beam radiotherapy

Jonas Schiffmann et al.

STRAHLENTHERAPIE UND ONKOLOGIE (2015)

添加到收藏夹

Article Medicine, General & Internal

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

David Moher et al.

SYSTEMATIC REVIEWS (2015)

添加到收藏夹

Editorial Material Oncology

Prostate Cancer and Prostatic Intraepithelial Neoplasia: True, True, and Unrelated?

Ian M. Thompson et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Oncology

High-Dose Radiotherapy With or Without Androgen Deprivation Therapy for Intermediate-Risk Prostate Cancer: Cancer Control and Toxicity Outcomes

Scott Edelman et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)

添加到收藏夹

Review Oncology

Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?

Zachary S. Zumsteg et al.

LANCET ONCOLOGY (2012)

添加到收藏夹

Article Medicine, General & Internal

Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer

Christopher U. Jones et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

添加到收藏夹

Article Immunology

Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses

Matthew D. Morse et al.

HUMAN IMMUNOLOGY (2010)

添加到收藏夹

Article Urology & Nephrology

Impact of Hormonal Therapy on Intermediate Risk Prostate Cancer Treated With Combination Brachytherapy and External Beam Irradiation

Richard G. Stock et al.

JOURNAL OF UROLOGY (2010)

添加到收藏夹

Article Oncology

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study

Michel Bolla et al.

LANCET ONCOLOGY (2010)

添加到收藏夹

Review Pharmacology & Pharmacy

Androgen deprivation therapy for prostate cancer

Eric A. Singer et al.

EXPERT OPINION ON PHARMACOTHERAPY (2008)

添加到收藏夹

Article Medicine, General & Internal

Androgen suppression and radiation vs radiation alone for prostate cancer - A randomized trial

Anthony V. D'Amico et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)

添加到收藏夹

Article Oncology

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

Milena Braga-Basaria et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

添加到收藏夹

Article Oncology

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial

JW Denham et al.

LANCET ONCOLOGY (2005)

添加到收藏夹

Article Oncology

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of Phase III RTOG 85-31

MV Pilepich et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)

添加到收藏夹

Article Medicine, General & Internal

Risk of fracture after androgen deprivation for prostate cancer

VB Shahinian et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

添加到收藏夹

Review Endocrinology & Metabolism

Androgen deprivation therapy for prostate cancer: Current status and future prospects

H Miyamoto et al.

PROSTATE (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.